<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884282</url>
  </required_header>
  <id_info>
    <org_study_id>COMBI-TED</org_study_id>
    <nct_id>NCT04884282</nct_id>
  </id_info>
  <brief_title>Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)</brief_title>
  <acronym>COMBI-TED</acronym>
  <official_title>A Multicenter, Phase II, Open Label, Randomized Trial Evaluating the Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Ricerca Traslazionale</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Ricerca Traslazionale</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, non-comparative, randomized study assessing combination of Tedopi with&#xD;
      docetaxel or with nivolumab in NSCLC patients failing after first- line chemoimmunotherapy.&#xD;
      In this non-comparative study, the standard arm (arm C) will serve as a calibration arm. All&#xD;
      NSCLC patients candidate for second- line therapy are considered eligible for the study if&#xD;
      they are HLA-A2+ and if they progressed after at least 4 cycles of previous first-line&#xD;
      chemo-immunotherapy. After evaluation of all inclusion and exclusion criteria and after&#xD;
      informed consent signature, all eligible patients will be treated with Tedopi plus docetaxel&#xD;
      (arm A) or Tedopi plus nivolumab (arm B) or docetaxel as single agent (arm C- standard arm).&#xD;
      Docetaxel therapy will be given until disease progression, unacceptable toxicity or patient&#xD;
      refusal, and up to maximum 6 cycles. Tedopi or nivolumab will be given until disease&#xD;
      progression, unacceptable toxicity or patient refusal.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 17, 2021</start_date>
  <completion_date type="Anticipated">May 17, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 17, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year Survival Rate</measure>
    <time_frame>1 year</time_frame>
    <description>1-year Survival Rate</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Metastatic Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A - tedopi + docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tedopi every 3 weeks plus docetaxel every 3 weeks only for 6 cycles, then maintenance with Tedopi alone every 6 weeks until the end of year 1, then every 12 weeks until disease progression, unacceptable toxicity or patient refusal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - tedopi + nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tedopi every 3 weeks plus nivolumab 360 mg every 3 weeks for 6 cycles, then maintenance nivolumab 360 mg every 3 weeks plus Tedopi every 6 weeks until the end of year 1, then every 12 weeks until disease progression, unacceptable toxicity or patient refusal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C - docetaxel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Docetaxel every 3 weeks until disease progression, unacceptable toxicity, patient refusal, or for a maximum of 6 cycles (whichever comes first).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tedopi</intervention_name>
    <description>TEDOPI is a T-specific immunotherapy was designed to induce cytotoxic T-lymphocytes against five five tumor associated antigens (ie CEA, p53, HER-2/neu, MAGE2 and MAGE3)</description>
    <arm_group_label>Arm A - tedopi + docetaxel</arm_group_label>
    <arm_group_label>Arm B - tedopi + nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains. Nivolumab is produced from cell culture using a CHO cell line.</description>
    <arm_group_label>Arm B - tedopi + nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel is a cytotoxic microtubule inhibiting antineoplastic agent in the taxane class. Docetaxel monotherapy is indicated for locally advanced or metastatic NSCLC after failure of prior platinum- based chemotherapy.</description>
    <arm_group_label>Arm A - tedopi + docetaxel</arm_group_label>
    <arm_group_label>Arm C - docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients willing and able to give written informed consent;&#xD;
&#xD;
          2. Histological or cytological confirmed diagnosis of HLA-A2+ NSCLC with no evidence of&#xD;
             EGFR mutations or ALK or ROS1 rearrangement;&#xD;
&#xD;
          3. Evidence of disease progression at the end of at least 4 cycles of chemo-immunotherapy&#xD;
             or 2 cycles of chemo-immunotherapy followed by 2 cycles of immunotherapy (CheckMate9LA&#xD;
             regimen) and eligible for treatment with docetaxel. This criterion implies that&#xD;
             patients with immunotherapy primary resistance are excluded;&#xD;
&#xD;
          4. Patients must have experienced progressive disease (PD), either during or within 3&#xD;
             months of discontinuing treatment with anti-PD-(L)1-based therapy, occurring after&#xD;
             previous clear benefit (any complete -CR- or partial response -PR), or after previous&#xD;
             stable disease (SD);&#xD;
&#xD;
          5. Performance status 0-1 (ECOG);&#xD;
&#xD;
          6. Patient compliance to trial procedures;&#xD;
&#xD;
          7. Age ≥ 18 years;&#xD;
&#xD;
          8. Adequate BM function (ANC ≥ 1.5x109/L, Platelets ≥ 100x109/L, HgB &gt; 9g/dl);&#xD;
&#xD;
          9. Adequate liver function (bilirubin &lt; G2, transaminases no more than 3xULN/&lt;5xULN in&#xD;
             present of liver metastases);&#xD;
&#xD;
         10. Normal level of creatinine;&#xD;
&#xD;
         11. Female patient: childbearing potential either terminated by surgery, radiation, or&#xD;
             menopause, or attenuated by use of approved contraceptive method [complete abstinence,&#xD;
             intrauterine contraceptive device (IUD), birth control pills, or barrier device] until&#xD;
             5 months after end of treatment.&#xD;
&#xD;
             or Male patient: should practice complete abstinence or if sexually active with WOCBP&#xD;
             must use any contraceptive method with failure rate less than 1%/year and they should&#xD;
             not donate semen as follows: in arm A and C until 6 months since the last dose of&#xD;
             docetaxel; in arm B until 3 months since last dose of tedopi.&#xD;
&#xD;
         12. Prior palliative radiotherapy to non-CNS lesions must have been completed at least 2&#xD;
             weeks prior to treatment. Subjects with symptomatic tumor lesions that may require&#xD;
             palliative radiotherapy within 4 weeks of first treatment are strongly encouraged to&#xD;
             receive palliative radiotherapy prior to treatment. Patients are eligible if CNS&#xD;
             metastases are adequately treated and patients are neurologically returned to baseline&#xD;
             (except for residual signs or symptoms related to the CNS treatment) for at least 2&#xD;
             weeks prior to randomization;&#xD;
&#xD;
         13. Patients must be either off corticosteroids, or on a stable or decreasing dose of ≤10&#xD;
             mg daily prednisone (or equivalent) for at least 2 weeks prior to randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient positive for actionable EGFR mutations or ALK or ROS1 rearrangement;&#xD;
&#xD;
          2. No previous chemoimmunotherapy for metastatic disease or evidence of disease&#xD;
             progression during the first 4 cycles of chemoimmunotherapy (primary resistance).&#xD;
             Patients with adjuvant resistance (documented loco-regionally and/or systemic relapse&#xD;
             of their disease occurring &lt;6 months after the last dose of anti-PD-(L)1-based&#xD;
             systemic adjuvant therapy) are excluded;&#xD;
&#xD;
          3. Patients with intervening systemic therapy following prior anti-PD-(L)1-based therapy;&#xD;
&#xD;
          4. Symptomatic brain metastases. Asymptomatic brain metastases are allowed if not&#xD;
             requiring corticosteroids use at a dose &gt;10mg daily prednisone (or equivalent);&#xD;
&#xD;
          5. Diagnosis of any other malignancy during the last 3 years, except for in situ&#xD;
             carcinoma of cervix uteri and cutaneous squamous cell carcinoma or other local tumors&#xD;
             considered cured;&#xD;
&#xD;
          6. Pregnancy or lactating;&#xD;
&#xD;
          7. Patients with an active, known or suspected autoimmune disease. Patients with type I&#xD;
             diabetes mellitus; hypothyroidism only requiring hormone replacement, skin disorders&#xD;
             (such as vitiligo, psoriasis, or alopecia) requiring systemic treatment, or conditions&#xD;
             not expected to recur in the absence of an external trigger are permitted to enroll;&#xD;
&#xD;
          8. Patients with a condition requiring systemic treatment with either corticosteroids (&gt;&#xD;
             10 mg daily prednisone equivalent) or other immunosuppressive medications within 14&#xD;
             days of randomization. Inhaled or topical steroids, and adrenal replacement steroid &gt;&#xD;
             10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune&#xD;
             disease;&#xD;
&#xD;
          9. Patients should be excluded if they are positive test for hepatitis B virus surface&#xD;
             antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or&#xD;
             chronic infection;&#xD;
&#xD;
         10. Patients should be excluded if they have known history of testing positive for human&#xD;
             immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Federico Cappuzzo, MD</last_name>
    <phone>+39 06.5266.5698</phone>
    <email>f.cappuzzo@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <state>Forlì</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Angelo Delmonte</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO Busto Arstizio PO Saronno</name>
      <address>
        <city>Saronno</city>
        <state>Varese</state>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Claudio Verusio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Sacro Cuore Don Calabria</name>
      <address>
        <city>Negrar</city>
        <state>Verona</state>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Stefania Gori</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Paolo</name>
      <address>
        <city>Civitavecchia</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Mario Rosario D'Andrea</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Francesca Mazzoni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOOR Papardo-Piemonte</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Vincenzo Adamo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU &quot;Maggiore della Carità&quot;</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Gloria Borra</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giulia Pasello</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Perugia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giulio Metro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS - Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Pagano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori &quot;Regina Elena&quot;</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Federico Cappuzzo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Sette Laghi</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Alessandro Tuzzi</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

